Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) EPS (Weighted Average and Diluted) (2016 - 2025)

Avalo Therapeutics' EPS (Weighted Average and Diluted) history spans 10 years, with the latest figure at -$0.37 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 121.51% year-over-year to -$0.37; the TTM value through Dec 2025 reached -$5.73, up 96.33%, while the annual FY2025 figure was -$5.84, 72.07% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.37 in Q4 2025 per AVTX's latest filing, up from -$2.19 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $117.47 in Q4 2023 to a low of -$1059.6 in Q4 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$74.34, with a median of -$2.1 recorded in 2021.
  • The largest YoY upside for EPS (Weighted Average and Diluted) was 116.27% in 2022 against a maximum downside of 54802.07% in 2022.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.93 in 2021, then tumbled by 54802.07% to -$1059.6 in 2022, then surged by 111.09% to $117.47 in 2023, then crashed by 98.54% to $1.72 in 2024, then tumbled by 121.51% to -$0.37 in 2025.
  • Per Business Quant, the three most recent readings for AVTX's EPS (Weighted Average and Diluted) are -$0.37 (Q4 2025), -$2.19 (Q3 2025), and -$1.92 (Q2 2025).